Neurogene Inc (NGNE) - Net Assets
Based on the latest financial reports, Neurogene Inc (NGNE) has net assets worth $264.89 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($289.18 Million) and total liabilities ($24.29 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check NGNE financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $264.89 Million |
| % of Total Assets | 91.6% |
| Annual Growth Rate | 27.75% |
| 5-Year Change | N/A |
| 10-Year Change | 83.1% |
| Growth Volatility | 1535.27 |
Neurogene Inc - Net Assets Trend (2011–2025)
This chart illustrates how Neurogene Inc's net assets have evolved over time, based on quarterly financial data. Also explore Neurogene Inc (NGNE) total assets for the complete picture of this company's asset base.
Annual Net Assets for Neurogene Inc (2011–2025)
The table below shows the annual net assets of Neurogene Inc from 2011 to 2025. For live valuation and market cap data, see Neurogene Inc (NGNE) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $264.89 Million | -14.66% |
| 2024-12-31 | $310.38 Million | +66.85% |
| 2023-12-31 | $186.02 Million | +88.61% |
| 2022-12-31 | $98.63 Million | +207.35% |
| 2021-12-31 | $-91.88 Million | -148.05% |
| 2020-12-31 | $191.22 Million | +34.96% |
| 2019-12-31 | $141.69 Million | +94.97% |
| 2018-12-31 | $72.67 Million | -26.51% |
| 2017-12-31 | $98.89 Million | -31.64% |
| 2016-12-31 | $144.66 Million | +33.43% |
| 2015-12-31 | $108.42 Million | +199.94% |
| 2014-12-31 | $36.15 Million | -29.52% |
| 2013-12-31 | $51.28 Million | +5767.59% |
| 2012-12-31 | $874.03K | -89.82% |
| 2011-12-31 | $8.59 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Neurogene Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 31279965300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $617.54 Million | 233.13% |
| Total Equity | $264.89 Million | 100.00% |
Neurogene Inc Competitors by Market Cap
The table below lists competitors of Neurogene Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chinese Maritime Transport Ltd
TW:2612
|
$336.60 Million |
|
Seah Steel Corp
KO:306200
|
$336.63 Million |
|
BRASI.CIA BRAS.D.PROP.ADR
F:52BA
|
$336.70 Million |
|
Profit Cultural & Creative Group Co Ltd
SHE:300640
|
$336.76 Million |
|
HCK Capital Group Bhd
KLSE:7105
|
$336.41 Million |
|
Youdao Inc
NYSE:DAO
|
$336.27 Million |
|
Echomarketing Co.Ltd
KQ:230360
|
$336.12 Million |
|
Deep Industries Limited
NSE:DEEPINDS
|
$336.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neurogene Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 310,375,000 to 264,887,000, a change of -45,488,000 (-14.7%).
- Net loss of 90,351,000 reduced equity.
- New share issuances of 30,380,000 increased equity.
- Other factors increased equity by 14,483,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-90.35 Million | -34.11% |
| Share Issuances | $30.38 Million | +11.47% |
| Other Changes | $14.48 Million | +5.47% |
| Total Change | $- | -14.66% |
Book Value vs Market Value Analysis
This analysis compares Neurogene Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.15x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 31.41x to 2.15x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $0.85 | $26.85 | x |
| 2012-12-31 | $0.09 | $26.85 | x |
| 2013-12-31 | $5.11 | $26.85 | x |
| 2014-12-31 | $4.17 | $26.85 | x |
| 2015-12-31 | $8.58 | $26.85 | x |
| 2016-12-31 | $7.66 | $26.85 | x |
| 2017-12-31 | $4.22 | $26.85 | x |
| 2018-12-31 | $3.09 | $26.85 | x |
| 2019-12-31 | $5.24 | $26.85 | x |
| 2020-12-31 | $3.69 | $26.85 | x |
| 2021-12-31 | $-1.67 | $26.85 | x |
| 2022-12-31 | $7.69 | $26.85 | x |
| 2023-12-31 | $14.51 | $26.85 | x |
| 2024-12-31 | $17.67 | $26.85 | x |
| 2025-12-31 | $12.51 | $26.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neurogene Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -34.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-34.11%) is above the historical average (-95.20%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -122.37% | 0.00% | 0.00x | 1.15x | $-11.37 Million |
| 2012 | -882.60% | 0.00% | 0.00x | 2.68x | $-7.80 Million |
| 2013 | -17.02% | 0.00% | 0.00x | 1.15x | $-13.86 Million |
| 2014 | -65.90% | 0.00% | 0.00x | 1.15x | $-27.44 Million |
| 2015 | -20.16% | 0.00% | 0.00x | 1.05x | $-32.70 Million |
| 2016 | -25.58% | 0.00% | 0.00x | 1.07x | $-51.47 Million |
| 2017 | -50.75% | 0.00% | 0.00x | 1.12x | $-60.07 Million |
| 2018 | -43.46% | -126.34% | 0.32x | 1.07x | $-38.85 Million |
| 2019 | -49.01% | 0.00% | 0.00x | 1.04x | $-83.61 Million |
| 2020 | -17.40% | 0.00% | 0.00x | 1.10x | $-52.40 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-41.33 Million |
| 2022 | -55.96% | 0.00% | 0.00x | 1.11x | $-65.05 Million |
| 2023 | -19.52% | 0.00% | 0.00x | 1.20x | $-54.92 Million |
| 2024 | -24.21% | -8123.68% | 0.00x | 1.08x | $-106.18 Million |
| 2025 | -34.11% | 0.00% | 0.00x | 1.09x | $-116.84 Million |
Industry Comparison
This section compares Neurogene Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neurogene Inc (NGNE) | $264.89 Million | -122.37% | 0.09x | $336.56 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Neurogene Inc
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disea… Read more